To determine the risk factors for EDin men treated by prostate brachytherapy (PB) for localized prostate cancer and to propose a model to predict post-implant erectile function. Out of a series of 270 sexually active men treated by PB, 241 (89%) (mean age ¼ 66 years (range, 43-80)) accepted to participate in a mail-based study on erectile function. The risk factors for erectile dysfunction were determined by regression analysis and a predictive model was proposed. The performance of the model was determined in this population and subsequently verified in a population of 50 men treated by PB in another treatment center. The risk factors for ED after PB were age, the pre-implant IIEF score and prostate volume. In the studied population, the final model to predict a posttreatment IIEF-5 score, using these factors, had a sensitivity of 69% and a specificity of 68% associated to an area under the ROC curve (AUC) of 0.75. The same performance was obtained in another treatment center. Age, pre-implant IIEF-5 score and prostate volume may be used to predict post-implant erectile function in patients treated by PB. 1,2 In a series of men treated for localized CaP, Bokhour et al.
INTRODUCTION
ED is a major preoccupation for prostate cancer (CaP) patients, especially younger ones. 1, 2 In a series of men treated for localized CaP, Bokhour et al. 3 found that ED affected not only the quality of sexual intimacy, but also everyday interaction with women, sexual imaging, fantasy life and the perception of manliness. Brachytherapy is a conservative treatment option for CaP that has a reputation of having a low morbidity on sexuality. A meta-analysis of 54 articles concluded that the predictive probability of maintaining erectile function was 0.76 after prostate brachytherapy (PB), 0.60 after PB plus external beam radiotherapy (EBR), 0.55 after EBR, 0.34 after nerve-sparing radical prostatectomy and 0.25 after standard radical prostatectomy. 4 However, the recommendations of the American Society of Brachytherapy illustrate an uncertainty concerning the patients who will develop erectile dysfunction following PB, concluding that both the severity and duration of morbidities after treatment (including ED) may vary from one patient to another. 5, 6 It is therefore interesting to create predictive tools providing individualized predictions based on the characteristics of one single patient. Nomograms, that are a graphic presentation of a mathematic model, provide the most objective, evidence-based, individualized risk estimation. 6 The goals of these tools are to provide patients with fuller information about their risk of developing a condition, to help patients decide which treatment approaches would result in the greatest benefit and, in addition, to develop more cost-effective interventions and to conceive new protocols of clinical research on ED.
The goal of the present study was to analyze the risk factors for ED in a population of men treated with 125 I PB who were sexually active before implantation and to propose a predictive model of erectile function after PB in Caucasian populations.
MATERIALS AND METHODS Patients
During the study period (2000) (2001) (2002) (2003) (2004) (2005) (2006) , the cancer center of the Claudius Regaud Institute in Toulouse was the unique center in the Midi-Pyrenees region (South West France) where PB was performed. Therefore, the candidate patients for this form of treatment were referred by urologists to this center. The necessary inclusion criteria were: CaP stage T1c/T2N0M0, Gleason score p7 (3 þ 4), PSA o10 ng ml À 1 , prostate volume o50 ml, no history of transurethral resection of the prostate, and an index of prostatic symptoms score (IPSS) o8.
Between 2000 and 2006, 316 consecutive patients were implanted with radioactive iodine 125 I seeds using a manual implantation technique with the Mick applicator and an intraoperative preplanning dosimetry based on the Variseed software (real-time computer-assisted dosimetry with dynamic seed localization performed in the operating theater). According to the post-treatment dosimetry, the mean dose to 90% of the outlined prostate volume (D90) was 160.5 Gy without any margins, using a modified uniform peripheral seed loading, and the mean percentage of the prostate volume receiving at least 100% of the prescribed dose (V100) was 88%. For all the patients, a post-implant domimetry was performed on a CT scan on D30. The post-implant dosimetry found a mean D90 of 160.5±22.2 Gy (97.5-222) and a V100 of 88±7.9 (61.8-99.5). Sixty-three (26%) patients received neoadjuvant androgen-deprivation therapy for a mean of 4 months (range 2-24 months). No patient received additional external beam radiation therapy or surgery potentially damaging to erectile function. A questionnaire on sexual activity (including the IIEF-5 questionnaire) was systematically completed by the patients before the beginning of treatment (during the preimplantation consultation).
Measures
Sociodemographic data, disease and treatment characteristics were recorded prospectively. A questionnaire explored all aspects of male sexuality. Data concerning ejaculation and orgasm have been published previously. 7, 8 Here, we present only the results relating to erectile function. 
Survey
The survey on sexual dysfunction was carried out in November 2006. Of the 316 patients, 28 men who were not sexually active before PB, eight who required a second implantation and 10 who had died (of causes unrelated to cancer) were excluded. One homosexual patient was included. After treatment, the 270 eligible patients were asked to participate in the survey of sexual dysfunction and were considered as suitable to participate if they completed the questionnaire. Only 29 refused to take part (participation rate: 89%). Finally, we obtained information about sexual function before and after PB in 241 patients. We checked that there were no significant differences in demographic, medical and PB parameters between responders and non-responders. Tables 1 and 2 summarize the characteristics of the population studied (n ¼ 241) and their treatment parameters. The mean interval between the end of treatment and post-treatment survey was 36 months (range 9-70 months).
At the same time, another study using the same questionnaire was carried out before and after implantation in a series of 50 patients treated by PB using the same technique in another treatment center (Orleans, France). The characteristics of this population and their treatment parameters are summarized in Table 3 .
Statistical methods
Statistical analyses were done using Stata 8 SE (Stata, College Station, TX, USA) with a 95% confidence interval (CI). Descriptive statistics were performed for all studied variables with a normality test for all quantitative variables. Inter-group comparisons were done using the w 2 test or Fisher's exact test for qualitative variables and the Mann-Whitney test for quantitative variables. As the IIEF and TSS scores did not follow a normal distribution, non-parametric tests were used. The Wilcoxon signed-rank test was used to compare scores (IIEF, TSS) before and after implantation.
A multiple correspondence analysis was done in order to give a comprehensive visualization of the relation between the IIEF score after implantation and the clinical and treatment parameters.
ED risk factors were studied by using the IIEF score after implantation which was treated as a binary variable (threshold ¼ 7). To evaluate the independent role of each variable, a univariate analysis was performed. A multivariate model, including all significant variables obtained from the univariate analysis, was used to assess the relation between IIEF and variables related to the patient. Odds ratio (OR) and 95% confidence intervals were obtained from unconditional logistic regression models.
This final model was used to predict the IIEF score on another population.
The accuracy of the model was tested by using two statistical analyses:
-The performance of the logistic regression model is illustrated by the sensitivity (proportion of patients with a IIEF score X7 that are correctly identified) and the specificity parameters (proportion of patients with a IIEF score o7 that are correctly identified) calibrated by a ROC (receiver operating characteristic) curve; an area under the ROC curve (AUC) of 0.50 represents a toss of a coin and an AUC of 1.0 represents perfect prediction. -The evaluation of prediction of the model was made with the test of Hosmer and Lemeshow, consisting of comparing the predictions obtained by the final model to the observations of the IIEF score after implantation.
RESULTS

Erectile function status
After implantation, patients had a significantly lower IIEF score than before implantation (13.2±7.5 vs 19.1±5.5; Po0.001). Figure 1 shows the repartition of patients by category of IIEF score before and after implantation.
The mean decrease in the IIEF score after PB was 7.2±6.3. Of the 216 patients who had a score X12 before PB (cutoff for intercourse with penetration), 32 (15%) ceased to be sexually active after treatment. Of the 184 patients who continued to be (Figure 2 ).
Risk factors for erectile dysfunction
Multiple correspondance analysis. In this analysis, we aimed to relate the score IIEF-5 after implantation with the clinical and treatment parameters (Figure 3 ). An IIEF score o7 after PB appeared to be linked to the presence of comorbid conditions (diabetes, obesity, history of cardiovascular disorders and contraindications to surgery) and/or neoadjuvant androgen-deprivation therapy.
Correlations. The IIEF score after PB was correlated with age at implantation (r ¼ 0.18, P ¼ 0.013) and with the IIEF score before PB (r ¼ 0.47, Po0.001). There was no correlation with PB parameters (D90, V100, V150, RV160, U30), nor with the length of time between the PB and evaluation.
Logistic regression. 
Use of the model in another population (n ¼ 50)
The characteristics of the Orleans patient population and their treatment parameters are summarized in Table 3 . The populations of Orleans and Toulouse differed from the age (P ¼ 0.048), the IPSS score (P ¼ 0.011), the volume of prostate (P ¼ 0.02), D90 (P ¼ 0.0001), V100 (P ¼ 0.0001) and V1500 (P ¼ 0.0001). The follow-up (average ¼ 69 months), the pre-implant IIEF-5 score and the IIEF-5 score at the time of the survey were not significantly different.
Using the data from the Orleans patients, the sensitivity and specificity obtained from the final model were 60 and 80%, respectively, and the surface under the ROC curve was 0.75.
The Hosmer-Lemeshow test indicated that the IIEF score after PB predicted by the final model were not significantly different from the observed IIEF score after PB (P ¼ 0.22).
DISCUSSION
One of the aims of our study was to clarify the risk of ED after PB in order to provide patients with fuller information. We identified three main risk factors for ED after PB: the pre-implant IIEF score, age and prostate volume. Interestingly, these factors are easy to assess preoperatively, which enables them to be used in a predictive model.
The Prostate Cancer Outcomes and Satisfaction With Treatement, Quality Assessment (PROSTQA), a prospective multicenter longitudinal study predicting long-term erectile function 2 years after CaP treatment, showed that pretreatment sexual healthrelated quality of life (HRQOL) score, young age, African American ethnicity and body mass index o25 were associated with erections suitable for intercourse two years after treatment. 11 In our study, all men were Caucasians, and the body mass index is not significant because of weak proportion of obese men.
Concerning the age, we found that the best cutoff age was 66 years. Surprisingly, the OR 41, meaning that patients younger than 66 are at a higher risk of ED. This finding was corroborated by the MacDonald study, 12 which showed in a multivariate model for ED that after PB, age was significant (with the median age of 65 in a cohort) with an OR 41. The meaning of erectile morbidity associated with younger age is uncertain. In a study of erectile morbidity through Medicare declarations of ED, and consultations related to ED treatment (for example, penile prostheses or intracavernosal injections), it was recognized that younger men are more likely to seek urologic consultations for ED or accept Erectile function after prostate brachytherapy E Huyghe et al invasive treatment of ED than older ones. 13 We also observed that in older patients, severe ED often resulted in the loss of sexual activity, whereas younger patients tried to maintain sexual activity. 14 The pre-implant IIEF score is a strong predictor of the postimplant IIEF score in the univariate analysis and remained significant on multivariate analysis, as suggested by many other authors. 15, 16, 11 Obviously, many etiologic factors of ED persist after PB (cardiovascular disorders, arterial damage, venous leakage, neurological factors), except psychogenic ones (anxiety, depression), that may be improved by cancer treatment. Considering that the pretreatment IIEF score is an independent indicator of post-treatment erectile function, we suggest that all newly diagnosed patients with CaP should receive screening for ED using the IIEF score, and that ideally this score be integrated into a predictive model, as we propose in this study.
Prostate volume was the third significant factor in the multivariate analysis. The patients with a small prostate volume had a high risk of severe ED post PB (Table 3) , independent of the bradytherapy parameters. McLaughlin et al. 17 highlighted the role of magnetic resonance imaging in prostate volume definition and implant quality evaluation. In our experience, the imaging technique used to calculate prostate volume (magnetic resonance imaging for the patients treated in Toulouse and by ultrasound for those treated in Orleans) does not seem to modify significantly the performance of the model.
Several anatomic structures involved in erectile function may be affected by PB in the case of a small prostate gland, due to an increased risk of radiation outside of the prostate.
Merrick et al. 16 observed a strong correlation between radiation doses to the bulb of the penis and erection dysfunction, however, other authors 12, 18 found no correlation between dose to either the penile bulb or NVBs and the development of post-implantation impotency. The internal pudendal arteries (IPA) are at risk of receiving an atherogenic dose of irradiation in patients treated by PB, as observed by Gillan et al. 19 in a study of 20 men treated by PB with determination by time-of-flight magnetic resonance angiography of the radiation dose received by the IPA. The authors found that the IPAs received a significant dose, particularly in the distal third of the IPA. They also observed that there was a trend for an inverse correlation between the IPA dose and prostate volume, and concluded that higher-activity seeds or more peripherally loaded extracapsular seed placement could also result in higher calculated doses to the IPAs. This may be sustained by anatomical description of the IPA, which are branches of the internal iliac artery running alongside the prostate as they course through the pelvis to vascularize erectile tissues of the penis.
Valdagni et al. 20 recently concluded that a lack of evidencebased knowledge of the anatomical regions involved in the expression of erectile dysfunction still persists. However, as we had not calculated the dose to the penile bulb or the IVA, this may contribute to the limitations of the study. Surprisingly, diabetes, obesity, cardiovascular diseases and medical contraindications to surgery and neoadjuvant androgendeprivation treatment (ADT) were not significant risk factors in our population.
For the latter factor, the situation seems different from what happens with EBR; several authors have shown that adjuvant androgen deprivation treatment (ADT) after EBR of the prostate reduces both sexual activity and erectile function. 21 The impact of androgen deprivation is long-acting, as highlighted by Zelefsky et al. 22 who found that the risk of ED persisted even 5 years after treatment in a series of 743 men treated by radiotherapy for CaP. However, the impact of ADT is also delayed, as shown by van de Wielen et al. 21 who observed that there was no difference in sexual activity between CaP patients treated with EBR þ ADT and those treated only with EBR during the first year. This may be the reason why neoadjuvant ADT, the mean duration of which was 4 months in our study, was not significant in our population.
With the three factors discussed above, the predictive factors of our model on 241 patients treated by PB in our institution were externally validated on an independent cohort of 50 patients with an AUC of 0.75, and were well calibrated with respect to observed outcomes. This corresponds to a rather good model. For example, the well-known nomogram made by Walz et al. 23 predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate-specific antigen had an AUC at 0.69. However, as erectile dysfunction is often multifactorial, the model may be improved by adding other factors that were not explored in the present study: for example, age of partner, marital status, frequency of intercourse, voiding function, psychological problems and apprehension about contaminating the partner, or pain during intercourse. We hope that a broader research including these factors will enable us to improve the performance of this preliminary model.
CONCLUSION
Patients often choose PB because it is reputed to be less damaging to erectile function; however, an uncertainty persists concerning the patients who will develop erectile dysfunction following PB. We identified that age, pre-implant IIEF score and prostate volume are significant risk factors for a post-implant IIEF score. These factors can be used in a predictive model with an AUC of 0.75. These preliminary results should be confirmed by further studies. 
